Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
JAZZ — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

6.13

Margin Of Safety %

30

Put/Call OI Ratio

0.9

EPS Next Q Diff

1.54

EPS Last/This Y

30.85

EPS This/Next Y

0.84

Price

256.5

Target Price

285.42

Analyst Recom

1.55

Performance Q

13.04

Upside

-26.5%

Beta

0.36

Ticker: JAZZ




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-07-13JAZZ2370.810.234876
2026-07-14JAZZ238.050.810.384879
2026-07-15JAZZ239.510.810.004895
2026-07-16JAZZ242.220.820.084865
2026-07-17JAZZ247.50.800.054934
2026-07-20JAZZ243.620.840.274624
2026-07-21JAZZ255.220.831.144660
2026-07-22JAZZ250.460.912.594947
2026-07-23JAZZ254.961.070.615489
2026-07-24JAZZ253.861.060.055500
2026-07-27JAZZ255.381.071.745488
2026-07-28JAZZ256.91.060.305512
2026-07-29JAZZ255.931.030.075707
2026-07-30JAZZ258.471.020.195738
2026-07-31JAZZ252.81.010.105779
2026-08-03JAZZ251.61.000.345793
2026-08-04JAZZ261.330.910.606449
2026-08-05JAZZ261.660.910.236310
2026-08-06JAZZ256.770.900.366353
2026-08-07JAZZ256.520.900.066352
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-07-13JAZZ236.87174.91127.425.28
2026-07-14JAZZ238.05174.91157.825.28
2026-07-15JAZZ239.57174.81160.625.28
2026-07-16JAZZ242.14174.81165.725.28
2026-07-17JAZZ247.56175.21175.825.35
2026-07-20JAZZ243.43175.21138.725.35
2026-07-21JAZZ254.40174.91197.625.31
2026-07-22JAZZ250.44174.91140.225.31
2026-07-23JAZZ254.91174.91172.025.31
2026-07-24JAZZ253.91174.91150.525.31
2026-07-27JAZZ255.44174.91159.925.31
2026-07-28JAZZ256.97174.91160.425.31
2026-07-29JAZZ255.85174.91150.625.31
2026-07-30JAZZ258.39174.91163.725.31
2026-07-31JAZZ252.51174.91132.125.31
2026-08-03JAZZ251.75174.91150.325.31
2026-08-04JAZZ251.75174.91150.325.31
2026-08-05JAZZ261.72174.9218.625.31
2026-08-06JAZZ256.84174.9199.825.31
2026-08-07JAZZ256.50-19.5217.725.01
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-07-13JAZZ-3.834.085.84
2026-07-14JAZZ-3.834.085.84
2026-07-15JAZZ-3.834.085.84
2026-07-16JAZZ-3.834.085.84
2026-07-17JAZZ-3.834.085.84
2026-07-20JAZZ-3.834.715.84
2026-07-21JAZZ-3.834.715.84
2026-07-22JAZZ-3.834.715.84
2026-07-23JAZZ-3.834.715.84
2026-07-24JAZZ-3.834.715.84
2026-07-27JAZZ-3.834.676.34
2026-07-28JAZZ-3.834.676.34
2026-07-29JAZZ-3.834.676.34
2026-07-30JAZZ-3.834.676.34
2026-07-31JAZZ-3.834.676.34
2026-08-03JAZZ-3.834.336.34
2026-08-04JAZZ-3.834.336.34
2026-08-05JAZZ-3.904.336.34
2026-08-06JAZZ-3.904.336.34
2026-08-07JAZZ-3.904.336.13
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

4.89

Avg. EPS Est. Current Quarter

6.54

Avg. EPS Est. Next Quarter

6.43

Insider Transactions

-3.9

Institutional Transactions

4.33

Beta

0.36

Average Sales Estimate Current Quarter

1210

Average Sales Estimate Next Quarter

1235

Fair Value

332.38

Quality Score

90

Growth Score

87

Sentiment Score

97

Actual DrawDown %

3.2

Max Drawdown 5-Year %

-42

Target Price

285.42

P/E

17.69

Forward P/E

9.9

PEG

0.19

P/S

3.62

P/B

3.46

P/Free Cash Flow

10.47

EPS

14.5

Average EPS Est. Cur. Y​

25.01

EPS Next Y. (Est.)

25.86

Target Price Estimates Raised

12

Target Price Estimates Lowered

Profit Margin

20.45

Relative Volume

1.1

Return on Equity vs Sector %

-7.7

Return on Equity vs Industry %

8.3

EPS 1 7Days Diff

-0.3

EPS 1 30Days Diff

-0.37

EBIT Estimation

217.7
JAZZ Healthcare
$256.56
📉
Swing / Pullback
Buy the dip on strong trends
34 /100
WEAK
Trend
0/20
Pullback
10/25
Volume
4/15
Valuation
12/20
TP/AR
4/10
Options
4/10
RSI
58.1
Range 1M
76%
Sup Dist
1.2%
🚀
Momentum Growth
Ride accelerating trends
N/A
50 /100
WEAK
Momentum
5/25
Growth
19/30
Estimates
10/20
Inst/Vol
9/15
Options
7/10
EPS Yr
198.7%
EPS NY
3.6%
52W%
95.1%
💎
Long-Term Value
Quality companies, undervalued
59 /100
WATCH
🟡 HOLD +26.6% upside
Quality
21/30
Valuation
17/30
Growth
15/25
Stability
5/10
LT Trend
1/5
Upside
+26.6%
Quality
90
MoS
30%
JAZZ — P/E HistoricalBiotechnology
Jazz Pharmaceuticals plc
Sector: Healthcare
Industry: Biotechnology
Employees: 2890
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
JAZZ

Latest News

Caricamento notizie per JAZZ
stock quote shares JAZZ – Jazz Pharmaceuticals plc Stock Price stock today
news today JAZZ – Jazz Pharmaceuticals plc stock forecast ,stock prediction 2023 2024 2025
marketwatch JAZZ – Jazz Pharmaceuticals plc yahoo finance google finance
stock history JAZZ – Jazz Pharmaceuticals plc invest stock market
stock prices JAZZ premarket after hours
ticker JAZZ fair value insiders trading
JAZZ — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

6.13

Margin Of Safety %

30

Put/Call OI Ratio

0.9

EPS Next Q Diff

1.54

EPS Last/This Y

30.85

EPS This/Next Y

0.84

Price

256.5

Target Price

285.42

Analyst Recom

1.55

Performance Q

13.04

Upside

-26.5%

Beta

0.36

Ticker: JAZZ




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-07-13JAZZ2370.810.234876
2026-07-14JAZZ238.050.810.384879
2026-07-15JAZZ239.510.810.004895
2026-07-16JAZZ242.220.820.084865
2026-07-17JAZZ247.50.800.054934
2026-07-20JAZZ243.620.840.274624
2026-07-21JAZZ255.220.831.144660
2026-07-22JAZZ250.460.912.594947
2026-07-23JAZZ254.961.070.615489
2026-07-24JAZZ253.861.060.055500
2026-07-27JAZZ255.381.071.745488
2026-07-28JAZZ256.91.060.305512
2026-07-29JAZZ255.931.030.075707
2026-07-30JAZZ258.471.020.195738
2026-07-31JAZZ252.81.010.105779
2026-08-03JAZZ251.61.000.345793
2026-08-04JAZZ261.330.910.606449
2026-08-05JAZZ261.660.910.236310
2026-08-06JAZZ256.770.900.366353
2026-08-07JAZZ256.520.900.066352
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-07-13JAZZ236.87174.91127.425.28
2026-07-14JAZZ238.05174.91157.825.28
2026-07-15JAZZ239.57174.81160.625.28
2026-07-16JAZZ242.14174.81165.725.28
2026-07-17JAZZ247.56175.21175.825.35
2026-07-20JAZZ243.43175.21138.725.35
2026-07-21JAZZ254.40174.91197.625.31
2026-07-22JAZZ250.44174.91140.225.31
2026-07-23JAZZ254.91174.91172.025.31
2026-07-24JAZZ253.91174.91150.525.31
2026-07-27JAZZ255.44174.91159.925.31
2026-07-28JAZZ256.97174.91160.425.31
2026-07-29JAZZ255.85174.91150.625.31
2026-07-30JAZZ258.39174.91163.725.31
2026-07-31JAZZ252.51174.91132.125.31
2026-08-03JAZZ251.75174.91150.325.31
2026-08-04JAZZ251.75174.91150.325.31
2026-08-05JAZZ261.72174.9218.625.31
2026-08-06JAZZ256.84174.9199.825.31
2026-08-07JAZZ256.50-19.5217.725.01
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-07-13JAZZ-3.834.085.84
2026-07-14JAZZ-3.834.085.84
2026-07-15JAZZ-3.834.085.84
2026-07-16JAZZ-3.834.085.84
2026-07-17JAZZ-3.834.085.84
2026-07-20JAZZ-3.834.715.84
2026-07-21JAZZ-3.834.715.84
2026-07-22JAZZ-3.834.715.84
2026-07-23JAZZ-3.834.715.84
2026-07-24JAZZ-3.834.715.84
2026-07-27JAZZ-3.834.676.34
2026-07-28JAZZ-3.834.676.34
2026-07-29JAZZ-3.834.676.34
2026-07-30JAZZ-3.834.676.34
2026-07-31JAZZ-3.834.676.34
2026-08-03JAZZ-3.834.336.34
2026-08-04JAZZ-3.834.336.34
2026-08-05JAZZ-3.904.336.34
2026-08-06JAZZ-3.904.336.34
2026-08-07JAZZ-3.904.336.13
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

4.89

Avg. EPS Est. Current Quarter

6.54

Avg. EPS Est. Next Quarter

6.43

Insider Transactions

-3.9

Institutional Transactions

4.33

Beta

0.36

Average Sales Estimate Current Quarter

1210

Average Sales Estimate Next Quarter

1235

Fair Value

332.38

Quality Score

90

Growth Score

87

Sentiment Score

97

Actual DrawDown %

3.2

Max Drawdown 5-Year %

-42

Target Price

285.42

P/E

17.69

Forward P/E

9.9

PEG

0.19

P/S

3.62

P/B

3.46

P/Free Cash Flow

10.47

EPS

14.5

Average EPS Est. Cur. Y​

25.01

EPS Next Y. (Est.)

25.86

Target Price Estimates Raised

12

Target Price Estimates Lowered

Profit Margin

20.45

Relative Volume

1.1

Return on Equity vs Sector %

-7.7

Return on Equity vs Industry %

8.3

EPS 1 7Days Diff

-0.3

EPS 1 30Days Diff

-0.37

EBIT Estimation

217.7
JAZZ Healthcare
$256.56
📉
Swing / Pullback
Buy the dip on strong trends
34 /100
WEAK
Trend
0/20
Pullback
10/25
Volume
4/15
Valuation
12/20
TP/AR
4/10
Options
4/10
RSI
58.1
Range 1M
76%
Sup Dist
1.2%
🚀
Momentum Growth
Ride accelerating trends
N/A
50 /100
WEAK
Momentum
5/25
Growth
19/30
Estimates
10/20
Inst/Vol
9/15
Options
7/10
EPS Yr
198.7%
EPS NY
3.6%
52W%
95.1%
💎
Long-Term Value
Quality companies, undervalued
59 /100
WATCH
🟡 HOLD +26.6% upside
Quality
21/30
Valuation
17/30
Growth
15/25
Stability
5/10
LT Trend
1/5
Upside
+26.6%
Quality
90
MoS
30%
JAZZ — P/E HistoricalBiotechnology
Jazz Pharmaceuticals plc
Sector: Healthcare
Industry: Biotechnology
Employees: 2890
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
JAZZ

Latest News

Caricamento notizie per JAZZ
stock quote shares JAZZ – Jazz Pharmaceuticals plc Stock Price stock today
news today JAZZ – Jazz Pharmaceuticals plc stock forecast ,stock prediction 2023 2024 2025
marketwatch JAZZ – Jazz Pharmaceuticals plc yahoo finance google finance
stock history JAZZ – Jazz Pharmaceuticals plc invest stock market
stock prices JAZZ premarket after hours
ticker JAZZ fair value insiders trading